Early observational studies suggested that hormone replacement therapy (HRT)  may improve cognitive functioning in postmenopausal women; however, larger studies, including the Women’s Health Initiative, have shown that estrogen replacement therapy started in postmenopausal women (65 [...]
 Multiple studies have demonstrated that the menopausal transition is associated with a 2- to 4-fold increased risk for clinically significant depressive symptoms. There have been several studies suggesting that hormone therapy may improve depressive [...]
For decades, estrogen was used as a component of hormone replacement therapy to treat menopausal symptoms, including hot flashes, night sweats, and sleep disturbance; however, after several large, prospective studies (e.g., HERS, WHI) questioned the [...]
While there have been concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain populations and that hormone replacement [...]
Because women appear to be at increased risk for new onset and recurrent depression as they transition into the menopause, it has been hypothesized that declining ovarian function -- or estrogen "withdrawal" -- may trigger [...]
Since the Women's Health Initiative (WHI) reported that the risks of menopausal hormone replacement therapy (HRT) outweighed its benefits, there has been a significant reduction in the use of HRT. Â However, since that time, studies [...]
Early observational studies suggested that postmenopausal hormone treatment may improve cognitive functioning in women; however, studies from the Women’s Health Initiative have shown that estrogen replacement therapy started in postmenopausal women (65 years or older) [...]
While there are concerns regarding the risks associated with prolonged use of hormone replacement, an increasing number of studies suggest that the risk may be relatively low in certain settings. A study presented this week at the Endocrine Society’s annual meeting which analyzed data from 43 randomized clinical trials suggests that menopausal hormone-replacement therapy does not appear to affect mortality either positively or negatively.
A study to be published in an upcoming issue of Menopause suggests that stellate ganglion blockade (SGB) may be an effective option for women with vasomotor symptoms (VMS), including hot flashes and night sweats. SGB is used primarily for pain management and involves the injection of local anesthetic into the stellate ganglion, part of the sympathetic nerve system located in the neck.
Following the publication of the Women's Health Initiative report in 2002, there was a dramatic drop in the use of hormone-replacement therapy (HRT) due to concerns about increased risk of heart disease, breast cancer, and stroke. Since that time, various non-hormonal alternatives have been utilized for the treatment of menopausal symptoms, including gabapentin and various serotonin reuptake inhibitors.
